JPRN-jRCT2041200093进行中（未招募）3 期
Open-Label, Single-Arm, Multicenter Study to Evaluate Long-Term Safety and Tolerability of Brivaracetam Used as Adjunctive Treatment in Pediatric Study Participants With Epilepsy - An open-label, long-term safety and tolerability study of brivaracetam as adjunctive treatment in pediatric study participants with epilepsy
Weihua Cai0 个研究点目标入组 79 人开始时间: 2021年1月27日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 79
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 1month old 至 <= 15age old（—）
- 性别
- All
入选标准
- •Inclusion criteria for long-term follow-up (LTFU) study participants only
- •- Study participants >=1 month of age with a confirmed diagnosis of epilepsy who participated in core study N01266 [NCT01364597] and/or N01349 [NCT03325439] and for whom a reasonable benefit from long-term administration of brivaracetam (BRV) is expected
- •Inclusion criteria for directly enrolled (DE) study participants only
- •- Study participant is >= 4 years to < 16 years of age
- •- Study participant has presence of an electroencephalogram (EEG) reading compatible with the diagnosis of focal epilepsy within the last 10 years
- •- Study participant has uncontrolled partial-onset seizure (POS) after an adequate course of treatment (in the opinion of the Investigator) with at least 1 antiepileptic drug (AED)
- •- Study participant had at least 1 POS during the 4-week Screening Period
- •- Study participant is taking at least 1 AED. Vagal nerve stimulator will be counted as a
- •concomitant AED
排除标准
- •Exclusion criteria for all study participants
- •- Study participant has, in the Investigator's opinion, severe medical, neurological, or psychiatric disorders or laboratory values, which may have an impact on the safety of the study participant.
- •- Study participant has end-stage kidney disease requiring dialysis or any medical condition including chronic liver disease (Child Pugh Score A, B, or C), which in the Investigator's opinion, warrants exclusion
- •- Study participant is currently participating in another study of an investigational medication (or a medical device) other than brivaracetam (BRV). The use of antiepileptic drugs (AEDs) marketed for adults but not approved for pediatric use is not considered to be investigational for the purposes of this study
- •- Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the Investigator or medical monitor, contraindicates participation in the study
- •Exclusion criteria for long-term follow-up (LTFU) study participants only
- •- Study participant had poor compliance with the visit schedule or medication intake in the BRV core study
- •- Study participant >= 6 years of age has a lifetime history of suicide attempt (including an actual attempt, interrupted attempt, or aborted attempt), or has suicidal ideation in the past 6 months as indicated on the Columbia Suicide Severity Rating Scale (C-SSRS)
- •Exclusion criteria for directly enrolled (DE) study participants only
- •- Study participant has a history of primary generalized epilepsy
- •- Study participant has a history of status epilepticus in the 30 days immediately prior to the Screening Visit (ScrV) or during the Screening Period
- •- Study participant has history or presence of known psychogenic nonepileptic seizures
- •- Study participant has experienced febrile seizures exclusively. The occurrence of febrile seizures in addition to other unprovoked seizures is not exclusionary
- •- Study participant has any clinically significant acute or chronic illness as determined during the physical examination or from other information available to the Investigator (eg, bone marrow suppression, chronic hepatic disease, severe renal impairment, psychiatric disorder as per Investigator assessment)
- •- Study participant has clinically significant laboratory abnormality that may increase the risk associated with study participation or may interfere with the interpretation of study results, according to the judgment of the Investigator
- •- Study participant has a clinically significant ECG abnormality according to the Investigator
- •- Study participant had major surgery within 6 months prior to the ScrV
研究者
相似试验
进行中（未招募）
1 期
A study to test the safety and tolerability of brivaracetam in pediatric study participants withseizures.MedDRA version: 21.0Level: PTClassification code 10015037Term: EpilepsySystem Organ Class: 10029205 - Nervous system disordersEpilepsyEUCTR2020-003664-29-BECB Biopharma SR100
进行中（未招募）
1 期
A study to test the safety and tolerability of brivaracetam in pediatric study participants withseizures.MedDRA version: 21.0Level: PTClassification code 10015037Term: EpilepsySystem Organ Class: 10029205 - Nervous system disordersEpilepsyEUCTR2020-003664-29-PLCB Biopharma SR79
进行中（未招募）
1 期
A study to test the safety and tolerability of brivaracetam in pediatric study participants withseizures.EpilepsyEUCTR2020-003664-29-HUCB Biopharma SR100
进行中（未招募）
1 期
A study to test the safety and tolerability of brivaracetam in pediatric study participants withseizures.EpilepsyEUCTR2020-003664-29-IECB Biopharma SR100
进行中（未招募）
1 期
A study to test the safety and tolerability of brivaracetam in pediatric study participants withseizures.MedDRA version: 21.0Level: PTClassification code 10015037Term: EpilepsySystem Organ Class: 10029205 - Nervous system disordersEpilepsyEUCTR2020-003664-29-DECB Biopharma SR100